Информация предназначена только для профессионалов в области здравоохранения.
Вы можете зайти как пользователь социальных сетей
1Developmental Imaging and Psychopathology Lab, Geneva, Switzerland 2Center for Contextual Psychiatry, Department of Neuroscience, KU Leuven, Leuven, Belgium 3Child and Adolescence Neuropsychiatry Unit, Department of Neuroscience, Bambino Gesù Children Hospital, Rome, Italy 4Developmental Clinical Psychology Unit, Faculty of Psychology, University of Geneva, Geneva, Switzerland 5Research Department of Clinical, Educational and Health Psychology, University College London, London, UK 6University Hospital of Child and Adolescent Psychiatry and Psychotherapy, University of Bern, Bern, Switzerland 7Department of Genetic Medicine and Development, School of Medicine, University of Geneva, Geneva, Switzerland
Список исп. литературыСкрыть список 1. Fusar-PoliP, BorgwardtS, BechdolfAetal. The psychosis high-risk state: a comprehensive state-of-the-art review. JAMA Psychiatry 2013;70:107-20. 2. Schultze-Lutter F, Debbané M, TheodoridouA et al. Revisiting the basic symptom concept: toward translating risk symptoms for psychosis into neurobiological targets. Front Psychiatry 2016;7:9. 3. Schultze-Lutter F, Michel C, Schmidt SJ et al. EPA guidance on the early detection of clinical high risk states of psychoses. Eur Psychiatry 2015;30:405-16. 4. Fusar-Poli P, Cappucciati M, Rutigliano G et al. At risk or not at risk?A meta-analysis of the prognostic accuracy of psychometric interviews for psychosis prediction. World Psychiatry 2015;14:322-32. 5. Insel TR. Rethinking schizophrenia. Nature 2010;468:187-93. 6. Bassett AS, McDonald-McGinn DM, Devriendt K et al. Practi-cal guidelines for managing patients with 22q11.2 deletion syn-drome. J Pediatr2011;159:332-9. 7. Schneider M, Debbané M, Bassett AS et al. Psychiatric disor-ders from childhood to adulthood in 22q11.2 deletion syndrome: results from the International Consortium on Brain and Behavior in 22q11.2 Deletion Syndrome. Am J Psychiatry 2014;171:627-39. 8. Armando M, Girardi P, Vicari S et al. Adolescents at ultra-high risk for psychosis with and without 22q11 deletion syndrome: a comparison of prodromal psychotic symptoms and general func-tioning. Schizophr Res 2012;139:151-6. 9. Debbané M, Glaser B, David MK et al. Psychotic symptoms in children and adolescents with 22q11.2 deletion syndrome: neuro-psychological and behavioral implications. Schizophr Res 2006;84:187-93. 10. Schneider M, Van der Linden M, Glaser B et al. Preliminary structure and predictive value of attenuated negative symptoms in 22q11.2 deletion syndrome. Psychiatry Res 2012;196:277-84. 11. Stoddard J, Niendam T, Hendren R et al. Attenuated positive symptoms of psychosis in adolescents with chromosome 22q11.2 deletion syndrome. Schizophr Res 2010;118:118-21. 12. Arinami T. Analyses of the associations between the genes of 22q11 deletion syndrome and schizophrenia. J Hum Genet 2006;51:1037-45. 13. Shprintzen RJ, Karayiorgou M, Morris MA et al. Schizophre-nia susceptibility associated with interstitial deletions of chromo-some 22q11. ProcNatlAcadSci USA 1995;92:7612-6. 14. Stefansson H, Rujescu D, Cichon S et al. Large recurrent microdeletions associated with schizophrenia. Nature 2008;455:232-6. 15. Sporn A, Addington A, Reiss AL et al. 22q11 deletion syn-drome in childhood onset schizophrenia: an update. Mol Psychia-try 2004;9:225-6. 16. Rockers K, Ousley O, Sutton T et al. Performance on the Modified Card Sorting Test and its relation to psychopathology in adolescents and young adults with 22q11.2 deletion syndrome. J Intellect Disabil Res 2009;53:665-76. 17. Shapiro DI, Cubells JF, Ousley OY et al. Prodromal symptoms in adolescents with 22q11.2 deletion syndrome and schizotypal personality disorder. Schizophr Res 2011;129:20-8. 18. Tang SX, Yi JJ, Calkins ME et al. Psychiatric disorders in 22q11.2 deletion syndrome are prevalent but undertreated. Psychol Med 2013;44:1-11. 19. Gothelf D, Schneider M, Green T et al. Risk factors and the evolution of psychosis in 22q11.2 deletion syndrome: a longitudi-nal 2-site study. J Am Acad Child Adolesc Psychiatry 2013;52:1192-203. 20. Vorstman JAS, Breetvelt EJ, Duijff SN et al. Cognitive decline preceding the onset of psychosis in patients with 22q11.2 deletion syndrome. JAMA Psychiatry 2015;72:377-85. 21. Radoeva PD, Fremont W, Antshel KM et al. Longitudinal study of premorbid adjustment in 22q11.2 deletion (velocardiofa-cial) syndrome and association with psychosis. DevPsychopathol (in press). 22. McGlashan T, Walsh BC, Woods SW. The psychosis-risk syndrome: handbook for diagnosis and follow-up. New York: Oxford University Press, 2010. 23. Schimmelmann BG, Michel C, Martz-IrngartingerA et al. Age matters in the prevalence and clinical significance of ultra-high-risk for psychosis symptoms and criteria in the general population: findings from the BEAR and BEARS-kid studies. World Psychia-try 2015;14:189-97. 24. Shaffer D, Gould MS, Brasic J et al. A children's global as-sessment scale (CGAS). Arch Gen Psychiatry 1983;40:1228-31. 25. Spitzer RL, Williams JB, Gibbon M et al. The Structured Clin-ical Interview for DSM-III-R (SCID). I: history, rationale, and description. Arch Gen Psychiatry 1992;49:624-9. 26. Reich W. Diagnostic interview for children and adolescents (DICA). J Am Acad Child Adolesc Psychiatry 2000;39:59-66. 27. Kaufman J, Birmaher B, Brent D et al. Schedule for Affective Disorders and Schizophrenia for School-Age Children-Present and Lifetime Version (K-SADS-PL): initial reliability and validity data. J Am Acad Child Adolesc Psychiatry 1997;36:980-8. 28. Wechsler D. The Wechsler Intelligence Scale for Children – third edition: administration and scoring manual. San Antonio: Psychological Corporation, 1991. 29. Wechsler D. Wechsler Adult Intelligence Scale – III: admin-istration and scoring manual. San Antonio: Psychological Corporation, 1997. 30. Achenbach TM, Rescorla LA. Manual for the ASEBA school-age forms and profiles. Burlington: University of Vermont, Research Center for Children, Youth, and Families, 2001. 31. Achenbach TM, Rescorla LA. Manual for the ASEBA adult forms and profiles. Burlington: University of Vermont, Research Center for Children, Youth and Families, 2003. 32. Kleinbaum DG, Klein M. Survival analysis: a self-learning text. New York: Springer, 2005. 33. Schneider M, Schaer M, Mutlu AK et al. Clinical and cognitive risk factors for psychotic symptoms in 22q11.2 deletion syndrome: a transversal and longitudinal approach. Eur Child Adolesc Psychiatry 2013;23:425-36. 34. Schultze-Lutter F, Michel C, Ruhrmann S et al. Prevalence and clinical significance of DSM-5-attenuated psychosis syndrome in adolescents and young adults in the general population: the Bern Epidemiological At-Risk (BEAR) study. Schizophr Bull 2014;40:1499-508. 35. Hartmann JA, Yuen HP, McGorry PD et al. Declining transi-tion rates to psychotic disorder in “ultra-high risk” clients: investi-gation of a dilution effect. Schizophr Res 2016;170:130-6. 36. Nelson B, Yuen HP, Wood SJ et al. Long-term follow-up of a group at ultra-high risk (“prodromal”) for psychosis: the PACE 400 study. JAMA Psychiatry 2013;70:793-802. 37. Nelson B, Yuen K, Yung AR. Ultra high risk (UHR) for psy-chosis criteria: are there different levels of risk for transition to psychosis? Schizophr Res 2011;125:62-8. 38. Schmidt SJ, Schultze-Lutter F, Schimmelmann BG et al. EPA guidance on the early intervention in clinical high risk states of psychoses. Eur Psychiatry 2015;30:388-404. 39. Fusar-Poli P, Bonoldi I, Yung AR et al. Predicting psychosis: meta-analysis of transition outcomes in individuals at high clinical risk. Arch Gen Psychiatry 2012;69:220-9. 40. Fusar-Poli P, Schultze-Lutter F. Predicting the onset of psychosis in patients at clinical high risk: practical guide to probabilistic prognostic reasoning. Evid Based Ment Health 2016;19:10-5. 41. Cornblatt BA, Carrión RE, AutherA et al. Psychosis preven-tion: a modified clinical high risk perspective from the Recognition and Prevention (RAP) program. Am J Psychiatry 2015;172:986-94. 42. Simon AE, Velthorst E, Nieman DH et al. Ultra high-risk state for psychosis and non-transition: a systematic review. Schizophr Res 2011;132:8-17. 43. Angkustsiri K, Leckliter I, Tartaglia N et al. An examination of the relationship of anxiety and intelligence to adaptive functioning in children with chromosome 22q11.2 deletion syndrome. J DevBehavPediatr2012;33:713-20. 44. Beaton EA, Simon TJ. How might stress contribute to in-creased risk for schizophrenia in children with chromosome 22q11.2 deletion syndrome? J NeurodevDisord2011;3:68-75. 45. Bartels-Velthuis AA, Jenner JA, van de Willige G et al. Prevalence and correlates of auditory vocal hallucinations in middle childhood. Br J Psychiatry 2010;196:41-6. 46. Bartels-Velthuis AA, van de Willige G, Jenner JA et al. Course of auditory vocal hallucinations in childhood: 5-year follow-up study. Br J Psychiatry 2011;199:296-302. 47. Cannon TD, Cadenhead K, Cornblatt B et al. Prediction of psychosis in youth at high clinical risk: a multisite longitudinal study in North America. Arch Gen Psychiatry 2008;65:28-37. 48. Seidman LJ, Giuliano AJ, Meyer EC et al. Neuropsychology of the prodrome to psychosis in the NAPLS consortium: relationship to family history and conversion to psychosis. Arch Gen Psychiatry 2010;67:578-88. 49. Thompson A, Nelson B, Yung A. Predictive validity of clinical variables in the “at risk” for psychosis population: international comparison with results from the North American Prodrome Longitudinal Study. Schizophr Res 2011;126:51-7. 50. Yuen T, Chow EWC, Silversides CK et al. Premorbid adjust-ment and schizophrenia in individuals with 22q11.2 deletion syn-drome. Schizophr Res 2013;151:221-5.